Health Care [ 10/12 ] | Biotechnology [ 46/75 ]
NASDAQ | Common Stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.
Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 26 | -1.21 Decreased by -3.30% | -0.05 Decreased by -2.32 K% |
| Nov 7, 25 | -0.06 Increased by +76.00% | -0.06 |
| Aug 7, 25 | -0.13 Increased by +63.89% | -0.16 Increased by +18.75% |
| May 13, 25 | -0.22 Increased by +35.29% | -0.18 Decreased by -22.22% |
| Mar 13, 25 | -1.17 Decreased by -405.62% | -0.22 Decreased by -431.82% |
| Nov 13, 24 | -0.25 Decreased by -47.06% | -0.30 Increased by +18.03% |
| Aug 9, 24 | -0.36 Increased by +74.83% | -0.32 Decreased by -12.50% |
| May 9, 24 | -0.34 Increased by +12.82% | -0.34 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | -26.00 K Decreased by -208.33% | -3.05 M Increased by +4.09% | Increased by +11.73 K% Increased by +188.54% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -2.67 M Increased by +23.97% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.54 M Increased by +48.96% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -3.35 M Increased by +27.29% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 24.00 K Decreased by -91.50% | -3.18 M Decreased by -0.31% | Decreased by -13.25 K% Decreased by -1.08 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.51 M Decreased by -50.84% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.97 M Decreased by -34.33% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -4.60 M Decreased by -244.41% | Decreased by N/A% Decreased by N/A% |